You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Droplet-Based Automation of Complex Workflows for Synthetic Biology

    SBC: ADVANCED LIQUID LOGIC            Topic: ST12B003

    Large-scale genome engineering represents a broad group of technologies, all of which stand to impact the manufacturing of a range of biological and chemical products. While the power of these methods to increase the production of biologically-driven manufacturing processes has been previously demonstrated, they are often developed and optimized toward a single target, or single methodology. Curre ...

    STTR Phase I 2013 Department of DefenseDefense Advanced Research Projects Agency
  2. Osteochondral tissue repair in an ovine model using a 3D woven poly (e-caprolacto

    SBC: Cytex Therapeutics, Inc.            Topic: NIA

    DESCRIPTION (provided by applicant): Standard microfracture is a first-line, widely used and cost-effective surgical technique for repairing damaged articular cartilage, but, it is limited by decreased long-term efficacy and limited applicability in largerlesions. This leads to a burgeoning economic burden associated with primary and follow-up treatment costs, estimated at more than 40 billion dol ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  3. Controlling mechanical signal transduction to treat osteoarthritis

    SBC: Cytex Therapeutics, Inc.            Topic: NIA

    DESCRIPTION (provided by applicant): Controlling mechanical signal transduction to treat osteoarthritis Abstract The TRPV4 calcium (Ca++) permeable ion channel has been shown to be expressed and functional in chondrocytes, the cells responsible for the maintenance of cartilage in weight-bearing joints. Trauma of joints with subsequent damage of cartilage, as well as chronically increased joint loa ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  4. Evaluation of a new class of molecules for treating MRSA infective endocarditis

    SBC: AGILE SCIENCES, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): Patients with infective endocarditis (IE) have a poor prognosis with one third of the patients succumbing to the infection within the first year. Treatments for endocarditis involve antibiotic therapy and/or surgery that cost upwards of 100,000 per patient; however, many cases do not respond to the antibiotic treatment and surgery poses high risks. Cases of en ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  5. Targeting c-Myc and Akt with PP2A reactivation therapy for the treatment of breas

    SBC: ONCOTIDE PHARMACEUTICALS, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): Each year in the United States over 270,000 women will be diagnosed with breast cancer and over 40,000 will die from the disease. While multiple forms of breast cancer exist, a common theme in most of the forms involvesaberrations in signal transduction pathways that lead to inhibition of the programmed cell death process known as apoptosis. Apoptosis is a care ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  6. Identification of potent and selective GLI1 inhibitors

    SBC: Zen-Bio, Inc.            Topic: NCI

    DESCRIPTION (provided by applicant): Characterization of human tumor samples and cell lines in combination with inhibitor studies in animal models has established a central role for the Hh pathway in a vast array of cancer types, including small-cell lung, pancreatic, oesophageal, prostate, breast, colon, liver and ovarian cancers. Hh signaling is now implicated in approximately 20-25% of all can ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  7. Urinary Biomarkers of Renal Mitochondrial Dysfunction

    SBC: SCHNELLGEN, INC.            Topic: NIEHS

    DESCRIPTION (provided by applicant): The long-term goal of this project is to identify and validate biomarkers of mitochondrial dysfunction due to environmental stressors. Diverse acute insults from surgery, trauma, ischemia/reperfusion (I/R) and drug andenvironmental chemical toxicity lead to mitochondrial dysfunction and result in cell injury and death in many organs/tissues (e.g. heart, lung, b ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  8. The Retroject Device: A Novel Approach to Glaucoma Drug Delivery

    SBC: RETROJECT, INC.            Topic: NEI

    PROJECT ABSTRACT Glaucoma is a common neurodegenerative disease which is the 2nd leading cause of blindness in the United States. With the aging baby boomer population, these numbers will continue to increase exponentially over the next few decades. With glaucomatous progression, there is ultimately damage to the optic nerve which results in peripheral vision loss. It has been shown in many prior ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  9. Nogo Decoy Receptor Therapy for the Treatment of Glaucoma

    SBC: ReNetX Bio, Inc.            Topic: NIMHD

    DESCRIPTION (provided by applicant): The objective of this phase I STTR application is to continue assessment of the relevance and feasibility of Nogo decoy receptor therapy for the treatment of glaucoma. The secondary objective is to obtain pharmacokinetic data important for designing additional preclinical efficacy studies and formulating a drug development plan for glaucoma. Our long term objec ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  10. Preclinical Development of Novel MEK1/2 Inhibitors to Treat Inherited Cardiomyopa

    SBC: CHEMINPHARMA, LLC            Topic: NCATS

    DESCRIPTION (provided by applicant): Cardiomyopathy is an anatomic and pathologic condition associated with muscle and electrical dysfunction of the heart, usually with inappropriate ventricular hypertrophy or dilatation. There are various causes of cardiomyopathy, many of which are genetic. Dilated cardiomyopathy, the most common form, is characterized by an increase in both myocardial mass and v ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government